Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches

被引：9
作者：
Achkar, Jacqueline M.
Casadevall, Arturo
Glatman-Freedman, Aharona
机构：
[1] Albert Einstein Coll Med, Div Infect Dis, Dept Pediat, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
[3] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA
[4] Albert Einstein Coll Med, Div Infect Dis, Dept Med, Bronx, NY 10461 USA
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2007年 / 5卷 / 03期
关键词：
antibodies; cytokines; immunotherapy; tuberculosis;
D O I：
10.1586/14787210.5.3.461
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The emergence of multidrug-resistant tuberculosis strains and the coinfection with HIV, together with advances in immunology, have led to renewed interest regarding ways to exploit the immune responses against Mycobacterium tuberculosis therapeutically. Here we review the fundamentals of tuberculosis therapy in view of the epidemiological and clinical challenges, and explore the experience with immune-based therapies for the treatment of active tuberculosis. These immune-based therapies are discussed here with the aim of assessing their potential use as adjuncts to chemotherapy.
引用
收藏
页码：461 / 474
页数：14
相关论文
共 122 条
[61]  
Holland S M, 2000, Adv Intern Med, V45, P431
[62]   TREATMENT OF REFRACTORY DISSEMINATED NONTUBERCULOUS MYCOBACTERIAL INFECTION WITH INTERFERON-GAMMA - A PRELIMINARY-REPORT [J].
HOLLAND, SM ;
EISENSTEIN, EM ;
KUHNS, DB ;
TURNER, ML ;
FLEISHER, TA ;
STROBER, W ;
GALLIN, JI .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (19) :1348-1355
[63]   RECOMBINANT INTERLEUKIN-2 LIMITS THE REPLICATION OF MYCOBACTERIUM-LEPRAEMURIUM AND MYCOBACTERIUM-BOVIS BCG IN MICE [J].
JEEVAN, A ;
ASHERSON, GL .
INFECTION AND IMMUNITY, 1988, 56 (03) :660-664
[64]   rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo [J].
Johnson, BJ ;
Bekker, LG ;
Rickman, R ;
Brown, S ;
Lesser, M ;
Ress, S ;
Willcox, P ;
Steyn, L ;
Kaplan, G .
TUBERCLE AND LUNG DISEASE, 1997, 78 (3-4) :195-203
[65]  
JOHNSON BJ, 1995, CYTOKINES MOL THER, V1, P185
[66]   Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis [J].
Johnson, JL ;
Ssekasanvu, E ;
Okwera, A ;
Mayanja, H ;
Hirsch, CS ;
Nakibali, JG ;
Jankus, DD ;
Eisenach, KD ;
Boom, WH ;
Ellner, JJ ;
Mugerwa, RD .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (02) :185-191
[67]   MICE THAT LACK THE INTERFERON-GAMMA RECEPTOR HAVE PROFOUNDLY ALTERED RESPONSES TO INFECTION WITH BACILLUS-CALMETTE-GUERIN AND SUBSEQUENT CHALLENGE WITH LIPOPOLYSACCHARIDE [J].
KAMIJO, R ;
LE, JM ;
SHAPIRO, D ;
HAVELL, EA ;
HUANG, S ;
AGUET, M ;
BOSLAND, M ;
VILCEK, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (04) :1435-1440
[68]   THE SYSTEMIC INFLUENCE OF RECOMBINANT INTERLEUKIN-2 ON THE MANIFESTATIONS OF LEPROMATOUS LEPROSY [J].
KAPLAN, G ;
BRITTON, WJ ;
HANCOCK, GE ;
THEUVENET, WJ ;
SMITH, KA ;
JOB, CK ;
ROCHE, PW ;
MOLLOY, A ;
BURKHARDT, R ;
BARKER, J ;
PRADHAN, HM ;
COHN, ZA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (04) :993-1006
[69]   Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [J].
Keane, J ;
Gershon, S ;
Wise, RP ;
Mirabile-Levens, E ;
Kasznica, J ;
Schwieterman, WD ;
Siegel, JN ;
Braun, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1098-1104
[70]   Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis [J].
Kim, H. J. ;
Kang, C. H. ;
Kim, Y. T. ;
Sung, S-W. ;
Kim, J. H. ;
Lee, S. M. ;
Yoo, C-G. ;
Lee, C-T. ;
Kim, Y. W. ;
Han, S. K. ;
Shim, Y-S. ;
Yim, J-J. .
EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (03) :576-580
234567891011